{"id":20148,"date":"2024-07-29T07:48:13","date_gmt":"2024-07-29T05:48:13","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=20148"},"modified":"2024-07-25T13:52:47","modified_gmt":"2024-07-25T11:52:47","slug":"amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick","status":"publish","type":"post","link":"https:\/\/www.m-q.ch\/fr\/amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick\/","title":{"rendered":"Amporin Pharmaceuticals re\u00e7oit CHF 150'000 de Venture Kick"},"content":{"rendered":"
\"\"
Cofondateurs d'Amporin : CSO Dr Herv\u00e9 Schaffhauser, CEO Dr Kelvin Stott, et CMO Prof. Daniel Umbricht. (Image : www.venturekick.ch)<\/figcaption><\/figure>\n

Plus de 50 maladies d\u00e9g\u00e9n\u00e9ratives mortelles, dont la maladie d'Alzheimer, la maladie de Parkinson, le diab\u00e8te de type II et de nombreuses maladies neurod\u00e9g\u00e9n\u00e9ratives rares, sont li\u00e9es \u00e0 un mauvais repliement et \u00e0 une agr\u00e9gation des prot\u00e9ines. Ces maladies touchent plus d'un demi-milliard de personnes dans le monde et font 3,6 millions de morts par an, ce qui co\u00fbte environ 3 milliards de dollars par an \u00e0 la soci\u00e9t\u00e9. Jusqu'\u00e0 pr\u00e9sent, il n'existe aucun traitement efficace pour arr\u00eater ou inverser la d\u00e9g\u00e9n\u00e9rescence progressive.\u00a0<\/p>\n

L'objectif d'Amporin Pharmaceuticals est de d\u00e9velopper une nouvelle classe de m\u00e9dicaments de faible poids mol\u00e9culaire qui bloquent et \u00e9liminent les oligom\u00e8res solubles toxiques et les pores dans les membranes cellulaires. Ces substances toxiques s'accumulent et d\u00e9truisent les cellules en per\u00e7ant des trous dans les membranes cellulaires, ce qui entra\u00eene une perte d'hom\u00e9ostasie et une d\u00e9g\u00e9n\u00e9rescence progressive. L'entreprise pr\u00e9voit de d\u00e9velopper et d'octroyer une licence pour les premiers traitements modificateurs de maladie efficaces, \u00e0 prendre par voie orale en urgence, pour jusqu'\u00e0 six maladies importantes, dont la maladie d'Alzheimer et le diab\u00e8te de type II, avec un accent initial sur la maladie de Parkinson et la SLA (scl\u00e9rose lat\u00e9rale amyotrophique).<\/p>\n

La maladie de Parkinson \u00e0 elle seule touche environ un million de personnes aux \u00c9tats-Unis et environ dix millions de personnes dans le monde. Le march\u00e9 mondial actuel des m\u00e9dicaments pour la maladie de Parkinson s'\u00e9l\u00e8ve \u00e0 environ 6 milliards de dollars par an, avec un march\u00e9 potentiel de 15 milliards de dollars par an pour les premiers traitements modificateurs efficaces de la maladie.<\/p>\n

Les 150 000 CHF de Venture Kick permettront \u00e0 l'entreprise d'\u00e9tablir ses activit\u00e9s principales et de cr\u00e9er un ensemble complet de donn\u00e9es in vitro afin de valider les avantages uniques de sa technologie et de les d\u00e9montrer aux investisseurs potentiels et aux partenaires de licence.<\/p>\n

L'\u00e9quipe fondatrice d'Amporin comprend le CEO Dr Kelvin Stott, le CSO Dr Herv\u00e9 Schaffhauser et le CMO Prof. Daniel Umbricht, qui ont chacun plus de 20 ans d'exp\u00e9rience dans le d\u00e9veloppement de m\u00e9dicaments pour le SNC et dans la direction de la recherche et du d\u00e9veloppement dans plusieurs grandes entreprises pharmaceutiques ainsi que dans des start-ups de biotechnologie.<\/p>\n

\"Venture Kick nous a apport\u00e9 un soutien d\u00e9cisif dans la cr\u00e9ation d'une entreprise de classe mondiale avec une technologie qui change le monde\", souligne Kelvin Stott, cofondateur et CEO d'Amporin Pharmaceuticals. \"Sans Venture Kick, nous n'aurions pas eu la possibilit\u00e9 de transformer notre potentiel en r\u00e9alit\u00e9\".<\/p>\n

Source : www.venturekick.ch<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"

Amporin Pharmaceuticals a re\u00e7u un investissement de CHF 150'000 de Venture Kick pour faire avancer le d\u00e9veloppement d'inhibiteurs de pores amylo\u00efdes pour le traitement de maladies d\u00e9g\u00e9n\u00e9ratives mortelles.<\/p>","protected":false},"author":380,"featured_media":20150,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3303],"tags":[5551,3327,3352,5549],"class_list":["post-20148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qualitaetsmanagement","tag-investition","tag-qualitaetsmanagement","tag-unternehmen","tag-venture-kick"],"acf":[],"yoast_head":"\nAmporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t<\/title>\n<meta name=\"description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m-q.ch\/fr\/amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta property=\"og:description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m-q.ch\/fr\/amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick\/\" \/>\n<meta property=\"og:site_name\" content=\"MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ManagementUndQualitaet\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"392\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta name=\"twitter:description\" content=\"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adelisa Kalajdzini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\"},\"headline\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"keywords\":[\"Investition\",\"Qualit\u00e4tsmanagement\",\"Unternehmen\",\"Venture Kick\"],\"articleSection\":[\"Qualit\u00e4tsmanagement\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"url\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"description\":\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"width\":680,\"height\":392,\"caption\":\"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Qualit\u00e4tsmanagement\",\"item\":\"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"name\":\"MQ Management und Qualit\u00e4t\",\"description\":\"Plattform f\u00fcr integrierte Managementsysteme.\",\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\",\"name\":\"Galledia Fachmedien AG\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"width\":512,\"height\":512,\"caption\":\"Galledia Fachmedien AG\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ManagementUndQualitaet\",\"https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\/\/www.m-q.ch\/fr\/author\/adelisa-kalajdzini\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amporin Pharmaceuticals re\u00e7oit 150'000 CHF de Venture Kick - MQ Management et Qualit\u00e9","description":"Amporin a re\u00e7u un investissement de 150 000 CHF de la part de Venture Kick afin de poursuivre le d\u00e9veloppement d'inhibiteurs de pores amylo\u00efdes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m-q.ch\/fr\/amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick\/","og_locale":"fr_FR","og_type":"article","og_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","og_description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","og_url":"https:\/\/www.m-q.ch\/fr\/amporin-pharmaceuticals-recoit-150000-chf-de-venture-kick\/","og_site_name":"MQ Management und Qualit\u00e4t","article_publisher":"https:\/\/www.facebook.com\/ManagementUndQualitaet","article_published_time":"2024-07-29T05:48:13+00:00","og_image":[{"width":680,"height":392,"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","type":"image\/jpeg"}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","twitter_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","twitter_description":"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.","twitter_image":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","twitter_misc":{"\u00c9crit par":"Adelisa Kalajdzini","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article","isPartOf":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175"},"headline":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick","datePublished":"2024-07-29T05:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"wordCount":375,"publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","keywords":["Investition","Qualit\u00e4tsmanagement","Unternehmen","Venture Kick"],"articleSection":["Qualit\u00e4tsmanagement"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","url":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","name":"Amporin Pharmaceuticals re\u00e7oit 150'000 CHF de Venture Kick - MQ Management et Qualit\u00e9","isPartOf":{"@id":"https:\/\/www.m-q.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","datePublished":"2024-07-29T05:48:13+00:00","description":"Amporin a re\u00e7u un investissement de 150 000 CHF de la part de Venture Kick afin de poursuivre le d\u00e9veloppement d'inhibiteurs de pores amylo\u00efdes.","breadcrumb":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","width":680,"height":392,"caption":"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Qualit\u00e4tsmanagement","item":"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/"},{"@type":"ListItem","position":2,"name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick"}]},{"@type":"WebSite","@id":"https:\/\/www.m-q.ch\/fr\/#website","url":"https:\/\/www.m-q.ch\/fr\/","name":"Gestion et qualit\u00e9 du QM","description":"Plate-forme pour les syst\u00e8mes de gestion int\u00e9gr\u00e9e.","publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.m-q.ch\/fr\/#organization","name":"Galledia Trade Media AG","url":"https:\/\/www.m-q.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","width":512,"height":512,"caption":"Galledia Fachmedien AG"},"image":{"@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ManagementUndQualitaet","https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.m-q.ch\/fr\/author\/adelisa-kalajdzini\/"}]}},"_links":{"self":[{"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/posts\/20148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/users\/380"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/comments?post=20148"}],"version-history":[{"count":2,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/posts\/20148\/revisions"}],"predecessor-version":[{"id":20151,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/posts\/20148\/revisions\/20151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/media\/20150"}],"wp:attachment":[{"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/media?parent=20148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/categories?post=20148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m-q.ch\/fr\/wp-json\/wp\/v2\/tags?post=20148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}